Effect of Human Immunoglobulin Combined with Bifid. Triple Viable in the Treatment of ABO Blood Group Incompatibility Hemolytic Neonates
Objective:To investigate the effect of human immunoglobulin combined with bifid.triple viable in the treatment of neonates with hemolysis caused by ABO blood group incompatibility. Methods:The clinical data of 106 cases of neonatal ABO-HDN admitted to our hospital from July 2019 to July 2024 were collected. According to the treatment methods,they were divided into experimental group (57 cases) and control group (49 cases). The control group was treated with human immunoglobulin,and the experimental group was treated with bifid.triple viable on the basis of the control group. The phototherapy time,jaundice regression time,hemoglobin (Hb) and total bilirubin (TSB) levels,complications and neurological development prognosis were compared between the two groups. Results:After treatment,the levels of Hb and TSB in the two groups were improved compared with those before treatment,but there was no significant difference in the level of Hb between the two groups after treatment (P>0.05),while the level of TSB in the experimental group was lower than that in the control group after treatment,and the daily decrease of TSB was greater than that in the control group,the difference was statistically significant (P<0.05). The disappearance time of skin yellow staining in the experimental group was shorter than that in the control group,the difference was statistically significant (P<0.05). There was no significant difference in phototherapy time between the two groups (P>0.05). The disappearance time of skin yellow staining in the experimental group was shorter than that in the control group,and the difference was statistically significant (P<0.05). The incidence of diarrhea in the experimental group was lower than that in the control group (P<0.05). There was no significant difference in the poor prognosis of nervous system between the two groups (P>0.05). Conclusion:Bifid.triple viable assisted human immunoglobulin in the treatment of neonatal ABO blood group incompatibility hemolysis can promote the regression of jaundice and reduce the occurrence of diarrhea,with good benefits.
Haemolytic disease of the newbornHuman immunoglobulinABO blood group incompatibilityBifid. Triple viable